How Do Ebglyss and Rinvoq Work for Eczema?
Ebglyss (lebrikizumab) is an IL-13 inhibitor that targets a specific protein driving skin inflammation in moderate-to-severe atopic dermatitis (eczema). Rinvoq (upadacitinib) is a JAK inhibitor that blocks multiple inflammatory signals inside cells. Both are approved for adults and adolescents with eczema not controlled by topical treatments, but they act through different pathways—Ebglyss more selectively on Th2 inflammation, Rinvoq more broadly.[1][2]
What Do Clinical Trials Show Head-to-Head?
No direct head-to-head trials compare Ebglyss and Rinvoq. Ebglyss trials (ADvocate1/2) showed 43% of patients achieving clear/almost clear skin (IGA 0/1) at week 16 with 250mg every 2 weeks, versus 13-16% on placebo. Rinvoq trials (Measure Up 1/2) reported 60-70% EASI-75 response (75% symptom reduction) at week 16 with 15mg daily, versus 8-15% placebo. Rinvoq edges out on speed and itch relief (80% report improvement by week 1), while Ebglyss sustains responses longer with less frequent dosing.[3][4]
Which Clears Skin Faster or Better Long-Term?
Rinvoq often clears skin faster—over 70% reach EASI-90 by week 52 in extensions, with rapid onset. Ebglyss hits 33% IGA 0/1 at week 16 but maintains it in 80%+ through year 1 with dosing every 2-4 weeks. Real-world data is limited, but Rinvoq shows higher peak efficacy; Ebglyss may suit maintenance with fewer injections.[1][5]
Side Effects and Safety Differences
Rinvoq carries black-box warnings for serious infections, heart issues, cancer, clots, and death—higher risks from broad JAK inhibition (e.g., 5-10% herpes zoster). Ebglyss has milder profile: mostly injection reactions (10-20%), conjunctivitis (5-10%), no major systemic warnings. Both increase infection risk, but Rinvoq requires monitoring for lipids, blood counts; Ebglyss avoids oral meds.[2][6]
Who Might Do Better on One Over the Other?
Rinvoq suits severe, urgent cases needing quick relief despite risks—often first-line biologic/JAK after Dupixent fails. Ebglyss fits patients prioritizing safety, convenience (biweekly subQ), or IL-13-driven eczema; it's newer (FDA-approved 2024) with less immunogenicity. Guidelines (e.g., AAD) rank both highly but favor JAKs like Rinvoq for rapid control, IL-13 like Ebglyss for tolerability.[7]
Cost and Access Factors
Rinvoq wholesales ~$6,000/month (15mg); Ebglyss ~$5,500/month (250mg). Insurance coverage varies—Rinvoq more established, Ebglyss gaining traction. No patent expiry soon: Rinvoq to 2033+, Ebglyss (Eli Lilly) protected into 2030s.[8]DrugPatentWatch.com
Sources:
[1] FDA Ebglyss label
[2] FDA Rinvoq label
[3] NEJM 2023; Lancet 2022 (Ebglyss/Rinvoq trials)
[4] JAAD 2024 meta-analysis
[5] Dermatology Times 2024 real-world
[6] Safety reviews, EMA/FDA
[7] AAD 2024 guidelines
[8] GoodRx pricing